Galectin Therapeutics Q1 net loss $0.19/share; cash $23.6M; NAVIGATE trial on track for Q4 2024 interim data

GALECTIN THERAPEUTICS INC

2024-Q1 EPS reported -$0.19

Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.
Cash and equivalents $23.6M; additional $20M available from chairman's credit lines (two $10M facilities).
Fifth DSMB recommended continuation of NAVIGATE Phase 2b/3 trial of belapectin in MASH cirrhosis without modifications.
Interim top-line data from Phase 2b portion expected late Q4 2024.
Appointed Khurram Jamil, M.D. as Vice President of Clinical Development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.

Period: the quarter ended March 31, 2024
Net income: net loss of $11.5 million
EPS: ($0.19) per share
Result: reported results

Exact text from the filing

For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-026106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.